WEEKLY IMPORTANT NEWS FROM MEDSCAPE AND OTHER SOURCES
Πέμπτη, 12 Ιανουαρίου 2017
DELAYED ADJUVANT CHEMOTHERAPY BENEFICIAL IN NSCLC
A new Yale study suggested that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to 4 months after surgery, according to the researchers. The study was published by Salazar et al in JAMA Oncology.
Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. For patients with non–small cell lung cancer (NSCLC), adjuvant chemotherapy has been shown to benefit patients with larger tumors or those with cancer in the lymph nodes.
While there is consensus regarding the use of chemotherapy after cancer surgery, the optimal timing is poorly defined. Many clinicians support starting chemotherapy within 6 to 9 weeks of surgery. But factors such as postoperative complications may affect a patient's ability to tolerate chemotherapy following surgery.
The study of 12,473 patients with stage I, II, or III disease who received chemotherapy suggests that the initiation of chemotherapy between 57 and 127 days postoperatively led to outcomes similar to those of patients who started closer to the currently recommended 6- to 9-week window, reported the researchers. Furthermore, delayed chemotherapy was associated with a lower risk of death compared to those patients treated only with surgery.
While the study results did not establish causality, they suggest a benefit of delayed chemotherapy for NSCLC patients, said Dr. Boffa.
“Patients treated surgically for NSCLC continue to benefit from chemotherapy when given outside the traditional postoperative window. Clinicians should still consider chemotherapy in appropriately selected patients who are healthy enough to tolerate it, up to 4 months after NSCLC surgical resection,” he said. “Further study is warranted to confirm these findings.”